LP
APLS

LMR Partners’s Apellis Pharmaceuticals APLS Stock Holding History

LMR Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,300
Closed -$810K – 990
2023
Q3 		$810K Buy
+21,300
New +$936K 0.01% 511

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

LMR Partners's APLS Position: Q2 2026 in Review

LMR Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 403,622 shares — an estimated $16.2M sold.

LMR Partners first reported a position in APLS in Q3 2021 and held it in 7 quarters. The position peaked at $16.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • LMR Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LMR Partners sold 403,622 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
  • LMR Partners first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • LMR Partners's Apellis Pharmaceuticals position peaked at $16.2M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.